Skip to content
Oncology Research Hub

Omaha, Nebraska

Cancer clinical trials in Omaha, NE

152 cancer studies are recruiting participants at sites in Omaha as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Omaha at a glance

  • 152 studies are recruiting at a site in Omaha.
  • By phase: Phase 1 (13), Phase 1/2 (25), Phase 2 (36), Phase 2/3 (7), Phase 3 (50), Phase 4 (3), No phase (8), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (94), university, hospital or other (48), government (10).
  • By research area: Breast Cancer (34), Lymphoma (33), Lung Cancer (31), Prostate Cancer (31), Pancreatic Cancer (15), Melanoma (8).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Omaha

Basic details from each study's public record (the 30 most recently updated of 152). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07748208 · updated
  2. Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    • Phase 1/2
    • All ages
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT06590857 · updated
  3. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT03723928 · updated
  4. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
    Registry record
    NCT07007559 · updated
  5. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
    Registry record
    NCT03424005 · updated
  6. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT07391774 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Lung cancer studies recruiting in Omaha

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07277413 · updated
  2. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Registry record
    NCT03460977 · updated
  3. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Oncology Hematology West P.C. dba Nebraska Cancer Specialists
    Registry record
    NCT07063745 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Nebraska Cancer Specialists/Oncology Hematology West PC - MECC · Nebraska Medicine-Village Pointe · Nebraska Methodist Hospital
    Registry record
    NCT04267848 · updated
  5. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Oncology Hematology West P.C. dba Nebraska Cancer Specialists · Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist · Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan
    Registry record
    NCT06758401 · updated
  6. Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
    Registry record
    NCT07845786 · updated
  7. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT07002034 · updated
  8. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT07472517 · updated
  9. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT04198766 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Prostate cancer studies recruiting in Omaha

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Alegent Health Bergan Mercy Medical Center
    Registry record
    NCT04423211 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)
    Registry record
    NCT06136624 · updated
  3. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT03866382 · updated
  4. RYZ711 Diagnostic Platform Study

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT07862582 · updated
  5. WATER IV PCa (AS Sub-study)

    • No phase
    • Ages 45 and older
    • Male participants
    Sponsor
    PROCEPT BioRobotics
    Study site
    Adult & Pediatric Urology
    Registry record
    NCT07650448 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Melanoma studies recruiting in Omaha

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT07068074 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT05136196 · updated
  3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Oncology Hematology West P.C. dba Nebraska Cancer Specialists
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Omaha, NE on ClinicalTrials.gov.

Lymphoma studies recruiting in Omaha

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06806033 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Of Nebraska Medical Center ( Site 0110)
    Registry record
    NCT06890884 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital and Medical Center of Omaha · University of Nebraska Medical Center
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Hospital and Medical Center of Omaha · Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT05675410 · updated
  5. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
    Registry record
    NCT06846671 · updated
  6. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT06649812 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Omaha, NE on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Omaha

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Ask about studies near Omaha

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call